286 related articles for article (PubMed ID: 27318098)
1. Current treatments for chronic hepatitis B virus infections.
Zoulim F; Lebossé F; Levrero M
Curr Opin Virol; 2016 Jun; 18():109-16. PubMed ID: 27318098
[TBL] [Abstract][Full Text] [Related]
2. Latest developments in the treatment of hepatitis B.
Dandri M; Petersen J
Minerva Gastroenterol Dietol; 2016 Mar; 62(1):88-102. PubMed ID: 26448309
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis B Virus Pregenomic RNA Is Present in Virions in Plasma and Is Associated With a Response to Pegylated Interferon Alfa-2a and Nucleos(t)ide Analogues.
Jansen L; Kootstra NA; van Dort KA; Takkenberg RB; Reesink HW; Zaaijer HL
J Infect Dis; 2016 Jan; 213(2):224-32. PubMed ID: 26216905
[TBL] [Abstract][Full Text] [Related]
4. HBeAg-positive chronic hepatitis B: why do I treat my patients with pegylated interferon?
Kao JH
Liver Int; 2014 Feb; 34 Suppl 1():112-9. PubMed ID: 24373087
[TBL] [Abstract][Full Text] [Related]
5. Why do I treat HBeAg-negative chronic hepatitis B patients with pegylated interferon?
Lampertico P; Viganò M; Colombo M
Liver Int; 2013 Feb; 33 Suppl 1():157-63. PubMed ID: 23286860
[TBL] [Abstract][Full Text] [Related]
6. Large-scale survey of naturally occurring HBV polymerase mutations associated with anti-HBV drug resistance in untreated patients with chronic hepatitis B.
Mirandola S; Campagnolo D; Bortoletto G; Franceschini L; Marcolongo M; Alberti A
J Viral Hepat; 2011 Jul; 18(7):e212-6. PubMed ID: 21692935
[TBL] [Abstract][Full Text] [Related]
7. Inhibiting the Secretion of Hepatitis B Surface Antigen (HBsAg) to Treat Hepatitis B Infection- a Review.
Baugh SDP
Infect Disord Drug Targets; 2017; 17(1):24-35. PubMed ID: 28056752
[TBL] [Abstract][Full Text] [Related]
8. Treatment of chronic hepatitis B.
Cornberg M; Jaroszewicz J; Manns MP; Wedemeyer H
Minerva Gastroenterol Dietol; 2010 Dec; 56(4):451-65. PubMed ID: 21139543
[TBL] [Abstract][Full Text] [Related]
9. HBeAg-negative chronic hepatitis B: why do I treat my patients with pegylated interferon-alfa?
Vlachogiannakos J; Papatheodoridis GV
Liver Int; 2014 Feb; 34 Suppl 1():127-32. PubMed ID: 24373089
[TBL] [Abstract][Full Text] [Related]
10. Sequential therapy with entecavir and pegylated interferon in a cohort of young patients affected by chronic hepatitis B.
Boglione L; Cariti G; Di Perri G; D'Avolio A
J Med Virol; 2016 Nov; 88(11):1953-9. PubMed ID: 27017932
[TBL] [Abstract][Full Text] [Related]
11. Peginterferon for the treatment of chronic hepatitis B in the era of nucleos(t)ide analogues.
Buster EH; Schalm SW; Janssen HL
Best Pract Res Clin Gastroenterol; 2008; 22(6):1093-108. PubMed ID: 19187869
[TBL] [Abstract][Full Text] [Related]
12. Early virologic response to pegylated interferon in chronic hepatitis B infection.
Ladep NG; Ugiagbe RA; Okonkwo U; Okeke EN; Malu AO
Niger J Med; 2009; 18(3):330-1. PubMed ID: 20120656
[TBL] [Abstract][Full Text] [Related]
13. Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients.
Yeh ML; Peng CY; Dai CY; Lai HC; Huang CF; Hsieh MY; Huang JF; Chen SC; Lin ZY; Yu ML; Chuang WL
PLoS One; 2015; 10(4):e0122259. PubMed ID: 25835020
[TBL] [Abstract][Full Text] [Related]
14. Individualized treatment of HBeAg-negative chronic hepatitis B using pegylated interferon-α2a as first-line and week-12 HBV DNA/HBsAg stopping rule: a cost-effectiveness analysis.
Iannazzo S; Coco B; Brunetto MR; Rossetti F; Caputo A; Latour A; Espinos B; Bonino F
Antivir Ther; 2013; 18(4):623-33. PubMed ID: 23486701
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerability of pegylated interferon-α-2a in chronic hepatitis B: a multicenter clinical experience.
Ratnam D; Dev A; Nguyen T; Sundararajan V; Harley H; Cheng W; Lee A; Rusli F; Chen R; Bell S; Pianko S; Sievert W
J Gastroenterol Hepatol; 2012 Sep; 27(9):1447-53. PubMed ID: 22168789
[TBL] [Abstract][Full Text] [Related]
16. The effect of pegylated interferon-alpha on the treatment of lamivudine resistant chronic HBeAg positive hepatitis B virus infection.
Leemans WF; Flink HJ; Janssen HL; Niesters HG; Schalm SW; de Man RA
J Hepatol; 2006 Mar; 44(3):507-11. PubMed ID: 16457904
[TBL] [Abstract][Full Text] [Related]
17. Prevention and management of drug resistant hepatitis B virus infections.
Wang C; Fan R; Sun J; Hou J
J Gastroenterol Hepatol; 2012 Sep; 27(9):1432-40. PubMed ID: 22694205
[TBL] [Abstract][Full Text] [Related]
18. Treatment of hepatitis B and C in children.
El-Shabrawi M; Hassanin F
Minerva Pediatr; 2014 Oct; 66(5):473-89. PubMed ID: 25253190
[TBL] [Abstract][Full Text] [Related]
19. Peginterferon and lamivudine for hepatitis B.
Assy NN; Hussein O
N Engl J Med; 2004 Dec; 351(27):2879; author reply 2879. PubMed ID: 15625344
[No Abstract] [Full Text] [Related]
20. A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B.
Piccolo P; Lenci I; Demelia L; Bandiera F; Piras MR; Antonucci G; Nosotti L; Mari T; De Santis A; Ponti ML; Sorbello O; Iacomi F; Angelico M
Antivir Ther; 2009; 14(8):1165-74. PubMed ID: 20032546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]